Ca 125 and Survival in Ovarian Cancer: Preliminary Communication
نویسندگان
چکیده
منابع مشابه
Serum CA 125 and ovarian cancer
of death from gynaecological cancer among women in Western countries. Epithelial ovarian cancer is responsible for 85-90% of all primary ovarian tumours. Because of the asymptomatic nature of the disease, ovarian cancer is usually not detected in the early stages and therefore many women present with advanced disease and systemic metastases. Approximately 70-80% of patients present with late st...
متن کاملCA 125 in ovarian cancer: advances and controversy.
Ovarian cancer continues to be a major health threat for women. The American Cancer Society estimates that in the United States in 1998, 25 400 new cases will be diagnosed and 14 500 women will die as a result of this disease (1). Most of these cancers are epithelial in origin, as germ cell tumors of the ovary represent only ;5% of the total. Approximately 70% of epithelial ovarian cancers will...
متن کاملA longitudinal analysis with CA-125 to predict overall survival in patients with ovarian cancer
OBJECTIVE The objective of this study was to explore the association of longitudinal CA-125 measurements with overall survival (OS) time by developing a flexible model for patient-specific CA-125 profiles, and to provide a simple and reliable prediction of OS. METHODS A retrospective study was performed on 275 patients with ovarian cancer who underwent at least one cycle of primary chemothera...
متن کاملUnderstanding CA 125 Levels A GUIDE FOR OVARIAN CANCER PATIENTS
The Foundation for Women's Cancer, formerly the Gynecologic Cancer Foundation, was established by the Society of Gynecologic Oncology in 1991 to increase funding for research and training, and to develop educational and awareness programs for women. These programs focus on the prevention, early detection and optimal treatment of gynecologic cancers. As a 501(c)(3) not-for-profit charitable orga...
متن کاملHE4, CA-125, and cystic ovarian mass
To the editor: The recent publication on ‘HE4, CA-125, and cystic ovarian mass’ is very interesting [1]. Partheen et al. [1] concluded that HE4 did not outperform CA-125. Indeed, the use of two biomarkers might be expected for increased screening ability; however, the problem of the cost should be kept in mind. Incremental analysis on additional cost should be done. Based on the present report,...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the Royal Society of Medicine
سال: 1988
ISSN: 0141-0768,1758-1095
DOI: 10.1177/014107688808100110